Obesity and hyperhomocysteinaemia after kidney transplantation

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 5, 2003, Pages

  Teplan, Vladimír ^a   Schück, Otto ^a   Štollová, Milena ^a   Vítko, Štefan ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Atherosclerosis; Hyperhomocysteinaemia; Hyperlipidaemia; Kidney transplantation; Leptin; Obesity

Indexed keywords

APOLIPOPROTEIN E; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROTEIN; LEPTIN; LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PYRIDOXINE; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; DIET THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERHOMOCYSTEINEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; PRAVASTATIN; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; VITAMIN B 6;

EID: 0042311429     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bostom AG, Gohh RY, Morrissey P. Hyperhomocysteinemia in chronic renal transplant recipients. Graft 2000; 3: 197-204
2. Wiecek A, Kokot F, Chudek J, Adamczak M. The adipose tissue-a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17: 191-193
3. Kokot F, Adamczak M, Wiecek A. Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 1998; 13: 2276-2280
4. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis 2001; 38 [Suppl 1]: S91-S94
5. Kasiske BL, Vasques MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 15 [Suppl 11]: S1-S86
6. Teplan V, Poledne R, Scück O, Ritz E, Vitko Š. Hyperlipidemia and obesity after renal transplantation. Ann Transplant 2001; 6: 21-23
7. Perna AF, Ingrasso D, De Santo NG. Metabolic consequences of folate induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8: 1899-1905
8. Kasiske BL, Guijarro C, Massy ZA et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158
9. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanism and management. J Am Soc Nephrol 1996; 7: 971
10. Praga M. Obesity-a neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17: 1157-1159